Cellular Genomics Appoints Dr. Peter Fuller Chief Business Officer

BRANFORD, Conn., March 9 /PRNewswire-FirstCall/ -- Cellular Genomics Inc. (CGI), a chemical genetics based biopharmaceutical company developing novel targeted therapeutics for cancer and angiogenesis, as well as allergic, autoimmune, and inflammatory diseases, today announced that Peter A. Fuller, Ph.D., has joined the Company in the newly created position of Chief Business Officer, reporting to Louis A. Matis, M.D., President and Chief Executive Officer. Prior to joining CGI, Dr. Fuller was Senior Vice President, Business Development at Molecular Staging, Inc.

"We are extremely pleased to have Peter join the management team at CGI, as he brings to the company broad knowledge of multiple facets of business and corporate development within a biotechnology setting," said Dr. Matis. "His extensive record of accomplishments encompasses product licensing, technology assessment, as well as research and development, all of which will prove to be invaluable as we increasingly leverage the partnering opportunities for our unique drug discovery capabilities and therapeutic programs."

Dr. Fuller, 50, has more than two decades of broad-based experience in the biotechnology industry. At Molecular Staging, Inc., Dr. Fuller was responsible for building and formalizing the company's business development functions, including the development and execution of short and long-term corporate development objectives, goals and strategies, as well as prioritizing technology, licensing, product development and marketing initiatives. Prior to joining Molecular Staging in 2001, Dr. Fuller was with Curagen Corporation since 1998, where first as Vice President and later, Senior Vice President, Business Development he had broad responsibility for business development and research and development. From 1983 to 1997, Dr. Fuller held positions of increasing responsibility at Pioneer Hi-Bred International, Inc., where he directed technology strategic planning activities, identified strategic alliance partners to meet the company's diverse product goals and was responsible for multiple licensing and R&D collaboration agreements. Dr. Fuller received his BS degree at the California State University at Chico and his MS and Ph.D. degrees from the University of Nebraska where he studied biometrical genetics.

"I am excited to be joining CGI at this critical juncture in the Company's growth," said Dr. Fuller. "CGI's drug discovery capabilities and growing pipeline of novel drug candidates are highly promising, and I look forward to applying my skills to lead CGI's business development initiatives."

About CGI:

Cellular Genomics Inc. (CGI) is a privately held genomics-based biopharmaceutical company with rapidly advancing drug development programs in oncology, angiogenesis, allergy, autoimmunity, and inflammation. CGI's proprietary technologies, including the company's unique, highly integrated chemical genetics ASKA (Analog Sensitive Kinase Allele) and state-of-the-art High-throughput Accelerated Lead Optimization (HALO) platforms, have demonstrated broad application across all phases of drug discovery, providing the company with key competitive advantages in identifying kinase inhibitors for multiple clinical indications. CGI is leveraging its broad capabilities to advance its own internal drug development programs as well as to establish partnerships with pharmaceutical and biotechnology companies. The Company has established research collaborations with Affymetrix, Eli Lilly and Company, Pfizer Inc., Schering AG, and Serono SA. Please visit http://www.cellulargenomics.com/ for additional information.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger-scale clinical trials and the risk that the company will not obtain approval to market its products.